RT @JohnEbbenMDPhD
From new validation for ✅Claudin 18.2 targeting in #gastricadenocarcinoma/#GEJ to ✅IO responses in MSS #colorectalcancer, #GI23 was full of big updates. Join #TumorBoardTuesday as @MPishvaian takes us through a recap of some of the big news coming out of GI ASCO. https://twitter.com/MPishvaian/status/1620588991828590592

RT @JohnEbbenMDPhD
Good to have a potential new option for patients w met #GEJ and #gastricadenocarcinoma that improves mOS. Should new frontline testing in #GEJ include:
🔹 MSI status
🔹 HER2
🔹 PD-L1 CPS
🔹 Claudin 18.2? https://twitter.com/MPishvaian/status/1620589414622834688

RT @JohnEbbenMDPhD
From new validation for ✅Claudin 18.2 targeting in #gastricadenocarcinoma/#GEJ to ✅IO responses in MSS #colorectalcancer, #GI23 was full of big updates. Join #TumorBoardTuesday as @MPishvaian takes us through a recap of some of the big news coming out of GI ASCO. https://twitter.com/MPishvaian/status/1620588991828590592

Good to have a potential new option for patients w met #GEJ and #gastricadenocarcinoma that improves mOS. Should new frontline testing in #GEJ include:
🔹 MSI status
🔹 HER2
🔹 PD-L1 CPS
🔹 Claudin 18.2?
---
RT @MPishvaian
#TumorBoardTuesday #GI23
@KoheiShitara 's presentation of FOLFOX+/-zolbetuximab in Gastric/GEJ jxn Ca wasn't just practice changing:
➡️~3 mo⬆️in mOS, achieving an 18.2 month mOS
✅A new standard of care👏

But it also vali…
https://twitter.com/MPishvaian/status/1620589414622834688

From new validation for ✅Claudin 18.2 targeting in #gastricadenocarcinoma/#GEJ to ✅IO responses in MSS #colorectalcancer, #GI23 was full of big updates. Join #TumorBoardTuesday as @MPishvaian takes us through a recap of some of the big news coming out of GI ASCO.
---
RT @MPishvaian
#TumorBoardTuesday #GI23
Don't know about you - but I was thrilled to👀my GI oncology colleagues in person

And the🖥️were great - several truly practice cha…
https://twitter.com/MPishvaian/status/1620588991828590592